Loading...

We've got a brand new version of Simply Wall St! Try it out

THC Farmaceuticals

OTCPK:CBDG
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CBDG
OTCPK
$4M
Market Cap
  1. Home
  2. US
  3. Commercial Services
Company description

THC Farmaceuticals, Inc. owns and operates non-financial institution cash-dispensing automated teller machines at third-party owned retail and commercial locations. The last earnings update was 1570 days ago. More info.


Add to Portfolio Compare Print
CBDG Share Price and Events
7 Day Returns
0%
OTCPK:CBDG
-1.7%
US Commercial Services
-1.4%
US Market
1 Year Returns
-58%
OTCPK:CBDG
18.7%
US Commercial Services
14.5%
US Market
CBDG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
THC Farmaceuticals (CBDG) 0% -6.5% -27.5% -58% 93.3% -73.6%
US Commercial Services -1.7% -0.1% 2.5% 18.7% 45.9% 79.4%
US Market -1.4% 1.3% 4.6% 14.5% 35.7% 48.6%
1 Year Return vs Industry and Market
  • CBDG underperformed the Commercial Services industry which returned 18.7% over the past year.
  • CBDG underperformed the Market in United States of America which returned 14.5% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

CBDG Value

 Is THC Farmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether THC Farmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as THC Farmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for THC Farmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $0.29.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for THC Farmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are THC Farmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:CBDG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2015-06-30) in USD Not available
OTCPK:CBDG Share Price ** OTCPK (2019-12-05) in USD $0.29
United States of America Commercial Services Industry PE Ratio Median Figure of 51 Publicly-Listed Commercial Services Companies 26.44x
United States of America Market PE Ratio Median Figure of 2,924 Publicly-Listed Companies 18.23x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of THC Farmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for THC Farmaceuticals, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does THC Farmaceuticals's expected growth come at a high price?
Raw Data
OTCPK:CBDG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Commercial Services Industry PEG Ratio Median Figure of 34 Publicly-Listed Commercial Services Companies 1.77x
United States of America Market PEG Ratio Median Figure of 2,045 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for THC Farmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on THC Farmaceuticals's assets?
Raw Data
OTCPK:CBDG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2015-06-30) in USD Not available
OTCPK:CBDG Share Price * OTCPK (2019-12-05) in USD $0.29
United States of America Commercial Services Industry PB Ratio Median Figure of 88 Publicly-Listed Commercial Services Companies 1.99x
United States of America Market PB Ratio Median Figure of 5,086 Publicly-Listed Companies 1.77x

* Primary Listing of THC Farmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. Examine THC Farmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Show me more potentially undervalued companies in the Commercial Services industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess THC Farmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Commercial Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Commercial Services industry average (and greater than 0)? (1 check)
  5. THC Farmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CBDG Future Performance

 How is THC Farmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as THC Farmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.7%
Expected Commercial Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is THC Farmaceuticals expected to grow at an attractive rate?
  • Unable to compare THC Farmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare THC Farmaceuticals's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare THC Farmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:CBDG Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Commercial Services Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Commercial Services Industry Revenue Growth Rate Market Cap Weighted Average 5.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:CBDG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:CBDG Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2015-06-30 0 -2 0
2015-03-31 0 0 0
2014-12-31 0 0 0
2014-09-30 0 0 0
2014-06-30 0 0 0
2014-03-31 0 0 0
2013-12-31 0 0 0
2013-09-30 0 0 0
2013-06-30 0 0 0
2013-03-31 0 0 0
2012-12-31 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if THC Farmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if THC Farmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:CBDG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from THC Farmaceuticals Company Filings, last reported 4 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CBDG Past Financials Data
Date (Data in USD Millions) EPS *
2015-06-30 -0.01
2015-03-31 0.00
2014-12-31 0.00
2014-09-30 0.00
2014-06-30 0.00
2014-03-31 0.00
2013-12-31 0.00
2013-09-30 0.00
2013-06-30 0.00
2013-03-31 0.00
2012-12-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if THC Farmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine THC Farmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. THC Farmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Commercial Services companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access THC Farmaceuticals's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess THC Farmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
THC Farmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CBDG Past Performance

  How has THC Farmaceuticals performed over the past 5 years?

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, THC Farmaceuticals has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data. You can see them here.

Show me the analysis anyway

  • THC Farmaceuticals's last earnings update was 1570 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare THC Farmaceuticals's growth in the last year to its industry (Commercial Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if THC Farmaceuticals's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare THC Farmaceuticals's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare THC Farmaceuticals's 1-year growth to the US Commercial Services industry average as past earnings data has not been reported.
Earnings and Revenue History
THC Farmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from THC Farmaceuticals Company Filings, last reported 4 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CBDG Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2015-06-30 0.02 -0.07 0.07
2015-03-31 0.02 -0.04 0.04
2014-12-31 0.02 -0.03 0.03
2014-09-30 0.02 -0.03 0.03
2014-06-30 0.02 -0.03 0.02
2014-03-31 0.02 -0.03 0.02
2013-12-31 0.02 -0.03 0.02
2013-09-30 0.02 -0.02 0.02
2013-06-30 0.02 -0.03 0.04
2013-03-31 0.03 -0.03 0.03
2012-12-31 0.03 -0.04 0.04

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if THC Farmaceuticals has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if THC Farmaceuticals has efficiently used its assets last year compared to the US Commercial Services industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if THC Farmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.

Next steps:

  1. Examine THC Farmaceuticals'sTHC Farmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access THC Farmaceuticals's filings and announcements here.
  3. Past financial records are usually unavailable for companies that have just been established or recently publicly listed, which makes them inherently riskier. Take a look at a list of well-established companies here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Past performance checks
We assess THC Farmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Commercial Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
THC Farmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CBDG Health

 How is THC Farmaceuticals's financial health and their level of debt?

In this section we usually analyse THC Farmaceuticals's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. THC Farmaceuticals has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information. You can see them here.

Show me the analysis anyway

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up THC Farmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as THC Farmaceuticals has not reported sufficient balance sheet data.
  • Unable to establish if THC Farmaceuticals's long term commitments exceed its cash and other short term assets as THC Farmaceuticals has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of THC Farmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if THC Farmaceuticals has a high level of physical assets or inventory without balance sheet data.
  • THC Farmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from THC Farmaceuticals Company Filings, last reported 4 years ago.

OTCPK:CBDG Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2015-06-30 1.01 0.68 0.03
2015-03-31 1.05 0.65 0.60
2014-12-31 0.03 0.01 0.00
2014-09-30 -0.05 0.08 0.00
2014-06-30 -0.04 0.08 0.00
2014-03-31 -0.04 0.07 0.00
2013-12-31 -0.03 0.06 0.00
2013-09-30 -0.02 0.06 0.00
2013-06-30 -0.01 0.06 0.00
2013-03-31 -0.01 0.05 0.00
2012-12-31 -0.01 0.04 0.00
  • THC Farmaceuticals has no debt.
  • THC Farmaceuticals currently has no debt however we can't compare to 5 years ago as we have no data for that period.
  • THC Farmaceuticals has no debt, it does not need to be covered by operating cash flow.
  • THC Farmaceuticals has no debt, therefore coverage of interest payments is not a concern.

Next steps:

  1. Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  2. Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when THC Farmaceuticals's financial data was last updated here.
  3. Companies with strong financial health are considered a less risky investment. Discover these stocks here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Financial health checks
We assess THC Farmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. THC Farmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CBDG Dividends

 What is THC Farmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from THC Farmaceuticals dividends.
If you bought $2,000 of THC Farmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate THC Farmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate THC Farmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:CBDG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Commercial Services Industry Average Dividend Yield Market Cap Weighted Average of 39 Stocks 1.6%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1958 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as THC Farmaceuticals has not reported any payouts.
  • Unable to verify if THC Farmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of THC Farmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as THC Farmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess THC Farmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can THC Farmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. THC Farmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CBDG Management

 What is the CEO of THC Farmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Gravel
AGE 89
TENURE AS CEO 4.6 years
CEO Bio

Senator Mike Gravel has been Chairman of the Board and Chief Executive Officer at THC Farmaceuticals, Inc. since May 15, 2015. Senator Gravel had been the Chief Executive Officer of Cannabis Sativa, Inc., since March 29, 2016 until January 09, 2019. Senator Gravel served as a U.S. Senator from Alaska from 1969 to 1981. He served as President and Chief Executive Officer of KUSH. Senator Gravel has been a Director of Cannabis Sativa, Inc. since October 01, 2014. Senator Gravel served as Director of Kush, Inc. from March 2013 to July 2014. Senator Gravel sat on the Finance, Interior, Environmental and Public Works committees and chaired the Energy, Water Resources, Buildings and Grounds and Environmental Pollution subcommittees. Senator Gravel is best known for his work on the Vietnam War. He filibustered for five months which contributed to the end of the military draft. He challenged the U.S. Government by releasing the Pentagon Papers. When the Nixon administration refused to allow the New York Times to publish information on the Pentagon Papers, Senator Gravel attempted to read the entire 7,000 pages of the document into the Senate record. The Supreme Court blocked his attempt. Senator Gravel then wrote The Senator Gravel Edition, The Pentagon Papers in 1971. He received a ruling that affected the Speech and Debate Clause of the Constitution. In retirement, Senator Gravel has written two books, Jobs and More Jobs and Citizen Power. He was a Democratic and Libertarian Party candidate for President of the United States in 2008. He co-authored A Political Odyssey and The King Makers. In 2008, Senator Gravel received the Columbia University School of General Studies' first annual Isaac Asimov Lifetime Achievement Award. He was the third Speaker of the Alaska House of Representatives. He graduated from the Columbia University School of General Studies and holds four honorary doctorate degrees.

CEO Compensation
  • Insufficient data for Mike to compare compensation growth.
  • Insufficient data for Mike to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team

Mike Gravel

TITLE
Chairman of The Board and Chief Executive Officer
AGE
89
TENURE
4.6 yrs

Ed Rosenthal

TITLE
President
TENURE
4.5 yrs
Board of Directors

Mike Gravel

TITLE
Chairman of The Board and Chief Executive Officer
AGE
89
TENURE
4.6 yrs

Travis Jenson

TITLE
Director
AGE
46
TENURE
9.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess THC Farmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. THC Farmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CBDG News

Simply Wall St News

CBDG Company Info

Description

THC Farmaceuticals, Inc. owns and operates non-financial institution cash-dispensing automated teller machines at third-party owned retail and commercial locations. The company’s machines are placed in hotels, stores, bowling alleys, and other high customer traffic areas for small and medium sized businesses. As of June 30, 2015, it had a total of eight machines for public use along the Wasatch Front in the State of Utah. The company was formerly known as City Media, Inc. and changed its name to THC Farmaceuticals, Inc. in February 2015. THC Farmaceuticals, Inc. was founded in 2008 and is based in Scottsdale, Arizona. THC Farmaceuticals, Inc. operates as a subsidiary of Weed Growth Fund, Inc.

Details
Name: THC Farmaceuticals, Inc.
CBDG
Exchange: OTCPK
Founded: 2008
$4,349,014
14,996,600
Website: http://www.thcpharmaceuticals.com
Address: THC Farmaceuticals, Inc.
7170 East McDonald Drive,
Suite 3,
Scottsdale,
Arizona, 85253,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK CBDG Common Stock Pink Sheets LLC US USD 23. Aug 2012
Number of employees
Current staff
Staff numbers
0
THC Farmaceuticals employees.
Industry
Diversified Support Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/12/06 00:29
End of day share price update: 2019/12/05 00:00
Last earnings filing: 2015/08/19
Last earnings reported: 2015/06/30
Last annual earnings reported: 2014/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.